Hyderabad–Pharma major Dr Reddy’s Laboratories Ltd on Wednesday announced that it has entered into a strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs).

The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the US, the Hyderabad-based company said in a release.

The combined sale of branded and generic versions of the products in the US is approximately $1 billion MAT for the most recent 12 months ending August 2016 according to IMS Health.

“Dr.Reddy’s Laboratories has a strong track record in developing, marketing and distributing generic injectables in the U.S. Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term,” said Alok Sonig, Executive Vice President and Head of North America, Dr Reddy’s.

“We are happy to expand our collaboration with Dr.Reddy’s for marketing and distribution of Gland Products in US and other Ex US markets. Dr.Reddy’s has an impressive track record of commercialising injectables products in the U.S, and we are confident that our partnership will continue to grow,” said Srinivas Sadu, Chief Operating Officer of Gland Pharma.